COMMUNIQUÉS West-GlobeNewswire

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
18/03/2024
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit [...]
Inovalon Announces Converged Submissions To Support Health Plan Risk Adjustment Programs
18/03/2024
Medicare and Commercial Affordable Care Act Plans Can Easily Deploy New Cloud-Based SaaS Solution to Submit Encounter Data to CMS to Support Their Risk Adjustment Programs, Improve Compliance, and Drive Stronger [...]
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
18/03/2024
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will [...]
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
18/03/2024
BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the [...]
Aruna Bio to Participate in Upcoming Investor Conferences
18/03/2024
BOSTON and ATHENS, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced that Stephen From, Chief [...]
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
18/03/2024
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31 [...]
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
18/03/2024
“Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey Meckler Registration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. ( [...]
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
18/03/2024
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX- [...]
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
18/03/2024
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a [...]
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
18/03/2024
Screening of subjects has begun at clinical study sites The Phase 2a study is being led by Principal Investigator, Dr. Stephen Harrison Aligos anticipates dosing the first subject in Q2 2024 with topline safety and [...]
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
18/03/2024
Phase 2a trial is on track to begin in the first half of 2024. Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration system, leading to [...]
Major shareholder announcement – BlackRock, Inc.
18/03/2024
ANNOUNCEMENT NO. 258 Major shareholder announcement Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec [...]
BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems
18/03/2024
Katie’s Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families BURLINGTON, Mass. and JERUSALEM, March 18, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ [...]
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
18/03/2024
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
18/03/2024
CELEBRATION, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a conference call and live [...]
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
18/03/2024
First patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX ® 3-71’s differentiated dual novel mechanism of action offers the potential to [...]
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
18/03/2024
- FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study - CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE [...]
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
18/03/2024
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
18/03/2024
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV [...]

Pages